Edition:
United States

People: Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

9.75EUR
8 Dec 2016
Change (% chg)

€-0.37 (-3.61%)
Prev Close
€10.11
Open
€10.14
Day's High
€10.14
Day's Low
€9.75
Volume
106,721
Avg. Vol
215,655
52-wk High
€16.20
52-wk Low
€8.21

Greig, Russell 

Dr. Russell G. Greig, Ph.D., is Independent Director of Ablynx NV. He has more than 30 years’ experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations. He spent the majority of his career at GlaxoSmithKline, where he held a number of positions including GSK’s President of Pharmaceuticals International from 2003 to 2008 and Senior Vice President Worldwide Business Development. From 2008 to 2010, Dr Greig was also President of SR One, GSK’s Corporate Venture Group. He is currently Chairman of AM Pharma and Mint Solutions (The Netherlands), a Board Member of Onxeo (France), as well as a Director of Tigenix (Belgium) and Oryzon (Spain). He also acts as Venture Partner to Kurma Life Sciences (France). He served as acting CEO at Genocea and Isconova for an interim period. He was a member of the Scottish Scientific Advisory Committee, reporting to the First Minister. He was also Chairman of Syntaxin (UK), which was acquired by Ipsen (France), Novagali (France) sold to Santen (Japan), and of Isconova (Sweden), acquired by Novavax (USA).

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --